Outcomes & Evidence: The Science of Ketamine and Psychedelic Therapy

Hundreds. A 2024 bibliometric analysis identified more than 925 peer-reviewed publications on ketamine and esketamine for depression alone since 2015, with research output continuing to accelerate (286 studies were published in 2024). When studies on ketamine for anxiety, PTSD, sleep, and other conditions are included, the total is substantially larger. Ketamine ranks among the most-studied novel mental health treatments of the past two decades, with foundational research dating to a landmark 2000 trial that has been called "the most improbable and transformative advance in depression pharmacotherapy in many decades."

Peer review is the standard mechanism for distinguishing reliable clinical findings from unverified claims. A treatment with published peer-reviewed outcomes has been independently evaluated for methodology, statistical rigor, and clinical relevance, which is the basis on which clinicians, researchers, and patients can trust it. Treatments, providers, and protocols without published outcomes can make claims about their effectiveness, but those claims cannot be independently verified.

Ketamine has been studied as a rapid-acting treatment for depression and other mental health conditions for more than two decades, with foundational research dating to the early 2000s at institutions including Yale, the National Institute of Mental Health, and Mount Sinai. It is among the most extensively studied mental health treatments of the past twenty years.

The full publication list lives on the Mindbloom Research page, linked from the Publications card on this hub. Each page on this hub also links to a plain-language summary of the underlying research, with the DOI for the peer-reviewed paper where applicable.

Real-world studies analyze outcomes from patients receiving care in standard clinical practice rather than under the controlled conditions of a randomized clinical trial. Real-world data captures how a treatment performs across a broader, more representative patient population and is increasingly used by regulators and clinicians to evaluate real-life effectiveness alongside RCT efficacy data.

Yes. Ketamine for depression has hundreds of peer-reviewed studies behind it, including randomized clinical trials, large-scale real-world outcomes analyses, and meta-analyses. The FDA approved an esketamine nasal spray (Spravato) for treatment-resistant depression in 2019, and clinical practice guidelines from the American Psychiatric Association include ketamine and esketamine as recommended options for treatment-resistant depression. The broader evidence base also covers anxiety, PTSD, sleep, and grief, with new research continuing to publish.